-+ 0.00%
-+ 0.00%
-+ 0.00%

AB Science suspends non-priority trials to focus on AML, ALS programs

PUBT·07/10/2026 15:50:36
Listen to the news
AB Science suspends non-priority trials to focus on AML, ALS programs
  • AB Science halted three non-priority masitinib trials to concentrate resources on AB8939 in acute myeloid leukemia, masitinib in ALS.
  • Stopped studies cover mast cell activation syndrome, mastocytosis, progressive multiple sclerosis; decision not tied to masitinib safety.
  • AB8939 program finished Phase 1 Step 3 with venetoclax; seeks clearance to start Phase 4 triple therapy with azacitidine.
  • ALS Phase 3 masitinib program, cleared in 2025, will be revised; regulators will be asked to restart via protocol amendment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB Science SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607101149PRIMZONEFULLFEED1001212263) on July 10, 2026, and is solely responsible for the information contained therein.